Press centre

Latest

15 Jun 2022

Shionogi, GARDP and CHAI announce landmark license and collaboration agreements to treat bacterial infections by expanding access to cefiderocol in 135 countries

Osaka (Japan), Geneva (Switzerland), Boston (USA), 15 June 2022 – Shionogi & Co., Ltd. (Shionogi) and the Global Antibiotic Research and Development Partnership (GARDP) have today announced the execution of a license and technology transfer agreement and, with the Clinton Health Access Initiative (CHAI), a collaboration agreement that aim to significantly transform the landscape of access to antibiotics […]

9 Jun 2022

GARDP Supports Bugworks in Assessing Safety of New Antibiotic Compound

10 May 2022

GARDP North America seeks an Executive Director – United States, Remote

26 Apr 2022

GARDP study reveals that babies are increasingly dying of neonatal sepsis caused by drug-resistant bacterial infections

22 Mar 2022

GARDP welcomes funding from the Australian Government to boost its critical work to tackle drug-resistant infections

10 Mar 2022

GARDP welcomes positive results in Venatorx phase 3 clinical trial of new treatment for serious bacterial infections

8 Feb 2022

Potentially life-saving treatment is safe to use for babies with neonatal sepsis, study reveals

Media contacts

For media inquiries, please contact the GARDP Communications Department:

Phone: +41 22 555 19 90 | Email: communications@gardp.org

Cookie Policy

We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.